Skip to content
Search

Latest Stories

Speculation about Kim Kardashian's weight loss leads to soaring demand for vital diabetes drug

A TikTok-fuelled stampede for the obesity drug has now led to a global shortage.

Speculation about Kim Kardashian's weight loss leads to soaring demand for vital diabetes drug

In February, the National Institute for Health, and Care Excellence (NICE) approved a weekly jab for obese patients with weight-related diseases, such as type 2 diabetes, or for those at high risk of a heart attack, as losing weight can help protect against these health issues.

However, when in May, reality TV star Kim Kardashian revealed that she had lost 16 lbs in three weeks to fit into a dress that once belonged to Marilyn Monroe, rumours began to circulate that she had used the drug semaglutide which is licensed for use only in those who are obese and suffering with health problems, the Daily Mail reports.


Speculation about Kardashian's weight loss led to high demand for the drug and a TikTok-fuelled stampede for the obesity drug has now led to a global shortage, leaving patients with severe health problems such as type 2 diabetes without the crucial treatment.

Though Kardashian has never commented on the claims, in one TikTok clip, viewed more than a million times, an evangelical patient speculates, ‘In my opinion, Kim’s drastic weight loss could be due to something like [semaglutide]… I might be wrong. These [medicines] are tools for people to completely metabolically change their bodies.’

The medication semaglutide, known by brand names Ozempic and Wegovy, is considered to be a major breakthrough, helping those who take it to shed almost a fifth of their weight.

Therefore, the hashtag #ozempic has garnered more than 270 million views on the social media platform, with hundreds of millions of views for #semaglutide, #wegovy, and similar hashtags.

In October, entrepreneur Elon Musk too had claimed on Twitter that he had lost weight due to the drug, semaglutide.

This drug reportedly works by suppressing appetite, and users apparently crave less and sometimes even forget to eat.

The phenomenal success of the drug has led to rising demand in the US, where about 40% of the population, is reportedly obese.

But apparently, semaglutide is also being prescribed to even those people who are not obese.

‘Styling teams for celebrities have come to accept the injections as part of grooming rituals,’ reports the entertainment magazine Variety. ‘It has become the worst-kept secret in Hollywood.’

The soaring demand has led to stocks of the drug running dry, and the drug’s manufacturer Novo Nordisk UK has established that it is ‘aware of a stock shortage.’

It adds, ‘Unprecedented demand has tested our manufacturing capacity. We are working to remedy this as soon as possible.’

Obesity expert Dr Carel le Roux, Professor of Metabolic Medicine at Ulster University is reported to have said, ‘Without semaglutide, patients relapse – they become incredibly hungry and are drawn to consume more food. They regain weight and their health suffers.’

According to experts, the drug works by mimicking the hormone glucagon-like peptide-1 (GLP-1), which is released after eating.

It signals to the body to release another hormone, known as insulin – this helps move digested sugar from the blood into cells where it can be used for energy, leading to a feeling of being full.

Trials of semaglutide last year caused a stir when it was revealed that patients, on average, lost 16% of their body weight after being on the drug for a year.

This result was reportedly seen even if the patients didn’t change their diet.

A private prescription for the drug costs roughly £100 a month, and many medics are of the opinion that obese patients should be offered the treatment on the NHS before the development of serious conditions such as type 2 diabetes.

‘Obesity is a disease that affects part of the brain involved with feelings of hunger,’ explains Prof le Roux, who runs the campaign group It’s Not Your Fault.

He adds, ‘It’s a biological problem that can’t be controlled with willpower.

‘Semaglutide targets the part of the brain affected by the disease of obesity. Ultimately the goal of treatment is to improve health, not what people see in the mirror.’

Although according to NICE semaglutide can be offered for two years only, Prof le Roux expects this to change.

He reportedly said, ‘There isn’t the evidence yet to show having patients on semaglutide for longer is cost-effective in terms of preventing illness.’

‘Next year we’ll have data to show whether or not the treatment reduces the risk of heart attacks. If it does, there will be a strong argument to put patients on it for life.’

Prof le Roux believes there is currently a shortage of semaglutide due to the staggering number of obese Americans who require it.

However, he warns that those who take this drug to get slim could be shocked by the consequences.

He states, ‘There is a rebound effect when the drug is stopped. Natural levels of GLP-1 will be lower, meaning patients will feel hungrier and end up heavier than before.

This drug will not make someone thin – it’s a treatment for obesity.’

More For You

Shabana Mahmood

Shabana Mahmood (Photo: Getty Images)

Calls grow for Shabana Mahmood to toughen settlement rules

HOME SECRETARY Shabana Mahmood is under pressure to immediately enforce stricter immigration rules as large numbers of migrants approach the point at which they can settle permanently in Britain.

Government figures revealed that from next year about 270,000 migrants will qualify for indefinite leave to remain (ILR), the legal right to stay in the UK. The number is expected to rise sharply, reaching more than 600,000 by 2028, reported the Times.

Keep ReadingShow less
Kamala Harris calls Biden’s 2024 run ‘recklessness’ in new memoir

Former US vice president Kamala Harris speaks at the Emerge 20th Anniversary Gala in San Francisco, California, on April 30, 2025. (Photo by CAMILLE COHEN/AFP via Getty Images)

Kamala Harris calls Biden’s 2024 run ‘recklessness’ in new memoir

FORMER US vice president Kamala Harris said it was "recklessness" to let Joe Biden run for a second term as president, in an excerpt released on Wednesday (10) from her upcoming memoir.

Harris -- who replaced Biden as the 2024 Democratic presidential candidate but lost to Donald Trump -- admitted that the then-81-year-old got "tired" and was prone to stumbles that showed his age.

Keep ReadingShow less
Tejasvi Manoj

Manoj, from Frisco, Texas, created an innovation called ‘Shield Seniors’, a website designed to help people over 60 identify and report fraudulent messages and emails. (Photo credit: LinkedIn/Tejasvi Manoj)

Indian-American teen Tejasvi Manoj named Time’s ‘Kid of the Year’ 2025

SEVENTEEN-year-old Indian-American Tejasvi Manoj has been named Time magazine’s ‘Kid of the Year’ for 2025 for her work on protecting senior citizens from online scams.

Manoj, from Frisco, Texas, created an innovation called ‘Shield Seniors’, a website designed to help people over 60 identify and report fraudulent messages and emails.

Keep ReadingShow less
Mark Rowley

Met chief Sir Mark Rowley (Photo: Getty Images)

Police watchdog calls for end to recording non-crime hate incidents

THE head of the police inspectorate has said that non-crime hate incidents should be scrapped, arguing that officers must draw a clear line between what is offensive and what is criminal.

Sir Andy Cooke, His Majesty’s Chief Inspector of Constabulary, made the comments as he released his annual report on the state of policing in England and Wales. He said that while much of the public expect officers to tackle serious crime and anti-social behaviour, too much time is being spent on matters that do not amount to criminality.

Keep ReadingShow less
 University of Kent

The Office for Students welcomed the move, saying more universities may look at mergers as many face financial difficulties. (Photo credit: University of Kent)

University of Kent

Kent and Greenwich to merge into UK’s first regional university group

THE UNIVERSITIES of Kent and Greenwich will merge in 2026 to form the UK’s first regional “super-university”.

The new institution, to be called the London and South East University Group, will have one vice-chancellor and around 50,000 students, the BBC reported.

Keep ReadingShow less